MELBOURNE, AUSTRALIA, Nov 29 (MARKET WIRE) -- Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced an update on itsPhase IIa clinical trial of PBT2 in patients with Alzheimer's disease.
